Anbio Biotechnology

NNNN Nasdaq SEC CIK 1982708
Follow Anbio Biotechnology Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 USD · US GAAP
EPS, diluted -

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
  • Revenue
  • Net income
$0$10M$20M$30MFY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$8.6M$6.4M
FY24$8.2M$2.4M
FY23$6.7M$2.3M
FY22$23.5M$10M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
0%25%50%75%100%FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2587.2%66.7%74.1%
FY2471.9%24.4%29%
FY2350.1%29.2%33.6%
FY2253.4%43.3%42.5%
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Anbio Biotechnology
  • Healthcare median
−100%−50%0%50%100%FY22FY23FY24FY25
Show the numbers
YearAnbio BiotechnologyHealthcare median
FY2574.1%−30.6%
FY2429%−47%
FY2333.6%−58%
FY2242.5%−80.4%